Brazilian Obesity Treatment Guidelines: New Focus on GLP-1 Medications

A new guideline from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) marks a significant shift in how doctors approach obesity treatment in Brazil. Released this Tuesday, the guideline dedicates specific recommendations to pharmacological interventions – medications – for the first time, with a particular focus on a relatively new class of drugs known as GLP-1 receptor agonists. This represents a growing recognition of the role medication can play, alongside lifestyle changes, in managing a complex and chronic disease.

Historically, guidance on obesity medications was embedded within broader treatment protocols. Now, Abeso has created a standalone document, signaling a change in perspective regarding the expanding toolkit available to clinicians. The move comes as advancements in pharmaceutical options offer more effective and, importantly, safer treatments for obesity, a condition affecting an estimated over 650 million adults worldwide, according to the World Health Organization.

A Broader Therapeutic Landscape

“In recent years, physicians have faced a much wider therapeutic landscape and increasingly individualized decision-making,” explains Fábio Trujilho, president of Abeso. The new guideline aims to provide clinicians with the support needed to navigate these complexities and ensure patient care is grounded in the latest evidence. It’s a response to the evolving understanding of obesity as a chronic disease, not simply a matter of willpower.

Alexandre Hohl, a director at Abeso and a contributor to the guideline, emphasizes the need for updated knowledge. “We’re living in a time of a plurality of medications. Ten or twenty years ago, we didn’t have pharmacological treatments with the efficacy and safety we have today,” he stated. “The arsenal we have now is large and growing, and doctors need to be aware of this, as most didn’t learn about these options during their training.”

GLP-1 Receptor Agonists: A New Era in Weight Management

Central to the updated guidance is the inclusion of GLP-1 receptor agonists. These medications, including semaglutide (found in Ozempic and Wegovy, manufactured by Novo Nordisk) and tirzepatide (Mounjaro, from Eli Lilly), mimic the action of the naturally occurring hormone GLP-1. This hormone plays a key role in regulating appetite and slowing gastric emptying, leading to increased feelings of fullness.

The potential impact of these drugs is substantial. Clinical trials have demonstrated that some patients can achieve weight loss exceeding 20% of their initial body weight – a level of weight reduction previously only achievable through bariatric surgery. This has led to considerable interest, and similarly some controversy, surrounding their use, particularly given off-label prescribing for weight loss when the medications were initially approved for diabetes management.

The guideline doesn’t endorse indiscriminate use. It stresses the importance of a comprehensive assessment of each patient, considering factors like overall health, existing medical conditions, and potential side effects. The medications are intended to be used in conjunction with lifestyle interventions – a balanced diet and regular physical activity – not as a standalone solution.

Beyond Medication: A Holistic Approach

Abeso’s guideline underscores that medication is just one component of effective obesity management. The organization continues to advocate for a holistic approach that addresses the underlying biological, psychological, and social factors contributing to the disease. This includes access to nutritional counseling, behavioral therapy, and support groups.

The guideline also acknowledges the importance of addressing the stigma associated with obesity. Healthcare providers are encouraged to create a supportive and non-judgmental environment for patients, recognizing that weight is influenced by a complex interplay of factors beyond individual control.

Who Benefits from These Medications?

The guideline outlines specific criteria for determining which patients might benefit from GLP-1 receptor agonists. Generally, these medications are considered for individuals with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with weight-related health complications such as type 2 diabetes, high blood pressure, or dyslipidemia (abnormal cholesterol levels). However, the decision to prescribe should always be made on a case-by-case basis, taking into account the patient’s individual circumstances.

Looking Ahead

The release of this guideline represents a crucial step forward in the fight against obesity in Brazil. Abeso plans to regularly update the document as new research emerges and new medications grow available. The organization is also working to educate healthcare professionals about the latest advances in obesity treatment and to promote a more comprehensive and compassionate approach to patient care. The next planned review of the guideline is scheduled for early 2025, to incorporate data from ongoing clinical trials and real-world usage of these newer medications.

This updated guidance offers a valuable resource for clinicians and patients alike, providing a framework for evidence-based decision-making in the management of a growing public health challenge. If you have concerns about your weight or are interested in learning more about obesity treatment options, please consult with your healthcare provider.

Disclaimer: This article provides general information and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance on obesity treatment.